Constrained Peptide Drugs Market, By Peptide Type (Cyclized Peptides, Macrocyclic Peptides, D-Peptides, and Stapled Peptides), By Therapeutic Area, By Synthesis Method, By Route of Administration, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4123
|
Published Date
July 2025
|
Pages
316
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Constrained Peptide Drugs Market size was valued at US$ 1,560.32 Million in 2024, expanding at a CAGR of 16.20% from 2025 to 2032.
Constrained peptide drugs are specially engineered molecules in which the peptide structure is chemically \"locked\" into a stable conformation. This structural constraint enhances the drug’s stability, improves its binding affinity to specific biological targets, and increases resistance to enzymatic degradation within the body. As a result, constrained peptides offer significant advantages over traditional peptides, including greater potency, improved selectivity, and prolonged therapeutic effects—making them highly effective in the treatment of various diseases.
Recognizing their therapeutic potential, governments and health agencies around the world are increasing investments in peptide-based drug research. According to the World Health Organization, more than 40 national health agencies have incorporated peptide therapeutics, including constrained peptides, into strategic biomedical innovation programs aimed at accelerating drug development for cancer, metabolic disorders, and infectious diseases.
Constrained Peptide Drugs Market- Market Dynamics
Rising Prevalence of Chronic Diseases to Drive Market Demand
The rising prevalence of chronic diseases is fueling the growth of the global constrained peptide drugs market. According to the CDC, approximately 6 in 10 adults in the U.S. suffer from a chronic condition, driving increased demand for targeted therapies such as constrained peptide drugs. Additionally, advancements in peptide stabilization technologies are expected to further accelerate market expansion. However, high production costs and regulatory hurdles may pose challenges to growth in the coming years. Conversely, the expanding use of constrained peptides in oncology and growing investments in personalized medicine present significant opportunities for the development of peptide drugs tailored to individual patient profiles.
Constrained Peptide Drugs Market- Segmentation Analysis:
The Global Constrained Peptide Drugs Market is segmented on the basis of Peptide Type, Therapeutic Area, Synthesis Method, Route of Administration, End User, and Region.
The global constrained peptide drugs market is segmented by peptide type into cyclized peptides, macrocyclic peptides, D-peptides, and stapled peptides. Among these, the cyclized peptides segment is expected to hold the largest market share during the forecast period. This dominance is primarily attributed to their enhanced stability, improved bioavailability, and broad therapeutic applications compared to other peptide types. Cyclized peptides offer superior resistance to enzymatic degradation and better target specificity, making them highly effective in drug development. According to the U.S. National Institutes of Health (NIH), peptide therapeutics have seen a compound annual growth rate (CAGR) exceeding 8% globally, with cyclized peptides representing a significant proportion due to their favorable pharmacokinetic properties.
In terms of therapeutic areas, the market is divided into infectious diseases, cardiovascular diseases, CNS disorders, oncology, and metabolic disorders. The oncology segment is projected to lead the market, driven by the rising prevalence of cancer worldwide and the proven efficacy of peptide drugs in targeted cancer therapies. Peptide-based drugs are increasingly utilized for their ability to precisely target tumor cells with minimal off-target effects. According to the World Health Organization (WHO), cancer remains a leading cause of death globally, with nearly 10 million deaths reported in 2023. Government initiatives, such as the U.S. Cancer Moonshot program, are fueling increased funding and research into novel cancer therapeutics, including constrained peptides, which further accelerates market growth in this segment.
Constrained Peptide Drugs Market- Geographical Insights
Geographically, North America is expected to maintain its position as the largest market for constrained peptide drugs during the forecast period. This is largely due to the region’s advanced healthcare infrastructure, substantial investments in research and development, and high adoption rates of innovative therapies. The U.S. Food and Drug Administration (FDA) reported a steady rise in approvals of peptide-based drugs, reflecting strong innovation within the biotechnology sector. Meanwhile, the Asia-Pacific region is projected to experience the fastest growth, propelled by increasing healthcare awareness, expanding patient populations, and growing investments in biotechnology and pharmaceutical industries across emerging economies such as China, India, and South Korea. Government support through policies like China’s “Made in China 2025” initiative and India’s pharmaceutical export promotion programs is catalyzing local development and adoption of advanced peptide therapeutics.
Constrained Peptide Drugs Market- Competitive Landscape:
Rising demand for targeted and stable therapeutics is driving innovation in constrained peptide drugs. Companies are prioritizing advancements in peptide stabilization technologies and delivery methods to enhance drug efficacy and improve patient compliance. Strategic partnerships and collaborations with research institutions are accelerating drug development and expanding product pipelines. Furthermore, increased investments in manufacturing capacity and market penetration in emerging regions are enabling companies to meet growing healthcare demands. A strong focus on personalized medicine and the development of novel peptide formats is further strengthening competitive positioning in this dynamic market.
Recent Developments:
- In January 2025, Bicycle Therapeutics plc announced updated Phase 1 combination trial results for zelenectide pevedotin with pembrolizumab in cisplatin-ineligible metastatic urothelial cancer patients, highlighting key achievements and outlining strategic plans for 2025.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amgen Inc.
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Sanofi S.A.
- Bicycle Therapeutics PLC
- Bristol-Myers Squibb Company
- Aileron Therapeutics, Inc.
- Eli Lilly and Company
- Aileron Therapeutics Inc.
- Spexis AG
- Santhera Pharmaceuticals
- Protagonist Therapeutics Inc.
- Union Chimique Belge S.A. (UCB)
- Biosynth (Pepscan)
- Creative Peptides
- Pepticom Ltd.
- Bio-Synthesis Inc.
- PeptiDream Inc.
- CPC Scientific Inc.
- Chugai Pharmaceutical Co. Ltd.
- Circle Pharma
- Others
GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY PEPTIDE TYPE- MARKET ANALYSIS, 2019 - 2032
- Cyclized Peptides
- Macrocyclic Peptides
- D-Peptides
- Stapled Peptides
GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Infectious Diseases
- Cardiovascular Diseases
- Cns Disorders
- Oncology
- Metabollic Disorders
GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY SYNTHESIS METHOD- MARKET ANALYSIS, 2019 - 2032
- Solid Phase Peptide Synthesis
- Recombinant Technology
GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Oral
- Intravenous
- Transdermal
- Subcutaneous
GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Research Institutes
- Pharmaceutical Companies
GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Constrained Peptide Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Constrained Peptide Drugs Market Snippet by Peptide Type
2.1.2. Constrained Peptide Drugs Market Snippet by Therapeutic Area
2.1.3. Constrained Peptide Drugs Market Snippet by Synthesis Method
2.1.4. Constrained Peptide Drugs Market Snippet by Route of Administration
2.1.5. Constrained Peptide Drugs Market Snippet by End User
2.1.6. Constrained Peptide Drugs Market Snippet by Country
2.1.7. Constrained Peptide Drugs Market Snippet by Region
2.2. Competitive Insights
3. Constrained Peptide Drugs Key Market Trends
3.1. Constrained Peptide Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Constrained Peptide Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Constrained Peptide Drugs Market Opportunities
3.4. Constrained Peptide Drugs Market Future Trends
4. Constrained Peptide Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Constrained Peptide Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Constrained Peptide Drugs Market Landscape
6.1. Constrained Peptide Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Constrained Peptide Drugs Market – By Peptide Type
7.1. Overview
7.1.1. Segment Share Analysis, By Peptide Type, 2024 & 2032 (%)
7.1.2. Cyclized Peptides
7.1.3. Macrocyclic Peptides
7.1.4. D-Peptides
7.1.5. Stapled Peptides
8. Constrained Peptide Drugs Market – By Therapeutic Area
8.1. Overview
8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
8.1.2. Infectious Diseases
8.1.3. Cardiovascular Diseases
8.1.4. Cns Disorders
8.1.5. Oncology
8.1.6. Metabollic Disorders
9. Constrained Peptide Drugs Market – By Synthesis Method
9.1. Overview
9.1.1. Segment Share Analysis, By Synthesis Method, 2024 & 2032 (%)
9.1.2. Solid Phase Peptide Synthesis
9.1.3. Recombinant Technology
10. Constrained Peptide Drugs Market – By Route of Administration
10.1. Overview
10.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
10.1.2. Oral
10.1.3. Intravenous
10.1.4. Transdermal
10.1.5. Subcutaneous
11. Constrained Peptide Drugs Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
11.1.2. Hospitals
11.1.3. Research Institutes
11.1.4. Pharmaceutical Companies
12. Constrained Peptide Drugs Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Constrained Peptide Drugs Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Constrained Peptide Drugs Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Constrained Peptide Drugs Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Constrained Peptide Drugs Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Constrained Peptide Drugs Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Constrained Peptide Drugs Industry
13.1. Competitive Dashboard
13.1.1. Competitive Benchmarking
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Amgen Inc.
13.2.2. Pfizer Inc.
13.2.3. Novartis AG
13.2.4. Merck & Co., Inc.
13.2.5. F. Hoffmann-La Roche Ltd.
13.2.6. Sanofi S.A.
13.2.7. Bicycle Therapeutics PLC
13.2.8. Bristol-Myers Squibb Company
13.2.9. Aileron Therapeutics, Inc.
13.2.10. Eli Lilly and Company
13.2.11. Aileron Therapeutics Inc.
13.2.12. Spexis AG
13.2.13. Santhera Pharmaceuticals
13.2.14. Protagonist Therapeutics Inc.
13.2.15. Union Chimique Belge S.A. (UCB)
13.2.16. Biosynth (Pepscan)
13.2.17. Creative Peptides
13.2.18. Pepticom Ltd.
13.2.19. Bio-Synthesis Inc.
13.2.20. PeptiDream Inc.
13.2.21. CPC Scientific Inc.
13.2.22. Chugai Pharmaceutical Co. Ltd.
13.2.23. Circle Pharma
13.2.24. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
